INTRODUCTION
Common variable immunodeficiency (CVID), the most frequent antibody deficiency syndrome, is associated with increased risk of bacterial infections, predominantly affecting the respiratory and gastrointestinal tracts (1) . CVID is a heterogeneous group of disorders and molecularly distinguished from X-linked agammaglobulinemia (XLA) and X-linked or non-Xlinked hyper-IgM syndrome (HIM) (1, 2) . Most CVID patients have normal numbers of circulating T and B cells. It has been suspected that CVID B cells fail to differentiate into plasma cells (2, 3) , leading to reduced serum immunoglobulin levels and abnormal antibody responses (4) . Almost four decades have passed since CVID was first described in 1953, and despite enormous progress in understanding the molecular basis of primary immunodeficiencies, the pathogenesis of CVID remains unclear (1) .
Memory B cells, which have undergone somatic hypermutation of immunoglobulin (Ig)-variable (V)-region genes, generate immunoglobulins of all isotypes rapidly and vigorously during the secondary immune response (5-7). The CD27 surface antigen, a type I glycoprotein belonging to the TNF receptor family (8) , has been shown to be a key surface marker for memory B cells (9 -12) . The ligand for CD27 (CD70) expressed by activated T and B cells promotes the differentiation of CD27
ϩ memory B cells into plasma cells (12) (13) (14) . CD27 is not expressed by cord blood B cells, and its expression on B cells increases gradually with age. In adults, approximately 40% of peripheral blood B cells are CD27
ϩ memory B cells (12) . Variation of CD27 expression on CVID B cells was reported (15) . We have previously shown by flow cytometric analysis that CD27 ϩ , especially IgD Ϫ CD27 ϩ , memory B cells are absent in patients with XHIM (16) . Recently, Revy et al. reported that CD27 ϩ B cells are found in peripheral blood of patients with non-X-linked HIM due to mutation of activation-induced cytidine deaminase (AID) (17) , whereas somatic hypermutation did not occur (18) . Several molecules such as phosphoinositide 3-kinase (PI3K), CD72, B LyS, and 8D6 were recently characterized as key molecules involved in B-cell activation, proliferation, and differentiation (19 -22) .
Although substantial progress has been made in understanding the molecular basis for the impaired immunoglobulin synthesis observed in many genetically defined primary immunodeficiencies, the mechanisms responsible for defective antibody synthesis in CVID have remained obscure. In this study, we examined the status of B-cell maturation in patients with CVID by analyzing IgD/CD27 expression, somatic hypermutation, and B-cell function in vitro.
MATERIALS AND METHODS

Patient Population
A total of 24 patients, 11 males and 13 females (mean age ϭ 43.0 years, ranging from 20 to 83 years), with well-documented CVID were included in this study (Table 1) . Seventeen patients (Patients 1-17) were from Seattle and Caucasians. Seven patients (Patients 18 -24) were Japanese. None of them had an affected relative. Serum IgA, IgM, and IgG levels were less than the age-matched control range in the majority of patients. All patients exhibited normal numbers of peripheral blood (PB) B cells (Ͼ1% of PB lymphocytes). If the B-cell percentage was Ͻ3%, XLA was excluded by examining the expression of Btk in monocytes and platelets by a flow cytometric analysis (23, 24) . CD154 (CD40 ligand) expression on PMA/ionomycin-activated CD4 ϩ T cells was determined by flow cytometry in all patients to exclude XHIM. The CD4/ CD8 ratio was normal in 20 patients and depressed (Ͻ0.7) in the remaining 4 patients. All but Patient 22 had late onset of clinical symptoms; the median age at the time of onset of symptoms or diagnosis was 29.0 years. Two patients presented with splenomegaly and thrombocytopenia (Patients 6 and 20). All but 5 patients received regular infusions of intravenous immunoglobulin at 2-to 4-week intervals.
Antibodies and Reagents
Mouse anti-CD27 mAb (8H5; IgG1), which does not block the ligation of CD27/CD70, mouse anti-Btk mAb (48-2H; IgG1), and mouse anti-CD70 mAb (HNE51; IgG1) were previously described (25) . Mouse anti-CD40 mAb (MAB89; IgG1) was purchased from Immunotech (Marseille, France). Polyclonal anti-IgD Ab, phycoerythrin (PE)-conjugated CD14 mAb (Tuk4; IgG2a), and PE-conjugated CD40 ligand (CD154) mAb (TRAP1; IgG1) were purchased from DAKO Japan (Tokyo, Japan), and PerCP-conjugated CD20 mAb was from Becton Dickinson (Mountain View, CA). Conjugation of biotin to anti-CD27 mAb was performed by standard techniques using N-hydroxysuccinimido-biotin (Sigma, St. Louis, MO). Staphylococcus aureus Cowan strain (SAC) was obtained from Sigma, IL-4 and IL-10 were from Genzyme (Boston, MA), and IL-2 was from Takeda Seiyaku Co. (Osaka, Japan).
Cell Preparation
Heparinized peripheral blood was collected from 24 patients with CVID, 3 patients with XLA, 3 with XHIM and concomitantly from healthy young adults after informed consent was obtained. Mononuclear cells (MNCs) were isolated by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient centrifugation.
Flow Cytometric Analysis
PB MNCs were stained with a combination of IgD-FITC, biotin-CD27 followed by streptavidin-PE and CD20-PerCP, followed by three-color analysis by FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA). In some experiments, MNCs were stimulated with 10 ng/ml of PMA (Life Technology, Grand Island, NY) and 1 g/ml of ionomycin (Sigma) for 8 h before staining with anti-CD4-FITC and anti-CD154-PE. Intracellular staining with anti-Btk mAb (48-2H) was performed as described previously (23, 24) . Briefly, primary MNCs and platelets were fixed in 4% paraformaldehyde in PBS and permeabilized in 0.1% Triton X-100 in PBS containing 1 mg/ml bovine serum albumin. Subsequently, cells and platelets were reacted with anti-Btk mAb or a control IgG1 mAbs (Dako Japan, Tokyo, Japan) and incubated with a FITC-conjugated goat anti-mouse Ig (Becton Dickinson) for 20 min. In some experiments, MNCs were stained with PE-labeled anti-CD20 (Dako Japan) or anti-CD14 mAb (Dako Japan), to identify B cells and monocytes, respectively. The stained cells were analyzed by FACScan (Becton Dickinson).
T-Cell Proliferation
PB MNCs (0.5 ϫ 10 6 /ml) were cultured in 96-well round bottom plates in a volume of 200 l/well with PHA (Wellcome, Bechenham, England) at 37°C in a humidified atmosphere with 5% CO 2 . After 3 days, the cultures were pulsed with 0.5 Ci 
Immunoglobulin Assay by ELISA
PB MNCs (0.5 ϫ 10 6 /ml for IgG, IgM, and IgA and 1 ϫ 10 6 /ml for IgE) were cultured at a volume of 200 l/well in 96-well plates with SACϩIL-2; IL-10ϩCD40 mAb was crosslinked by CD32 transfectants (CD40/ CD32T), which were prepared as described elsewhere (26); SACϩIL-2ϩCD40/CD32TϩIL-10 or IL-4ϩCD40/ CD32T was cultured for 8 days (IgG, IgM, and IgA); and cultures containing IL-4, IL-4 plus CD40 mAb, or IL-4 and CD40/CD32T were incubated for 12 to 14 days for IgE production at 37°C in a humidified atmosphere with 5 % CO 2 . The supernatants were harvested and added to goat anti-human Ig (Southern Biotechnology) or anti-IgE (CIA-E-7.12 and CIA-E-4.15, kindly provided by A. Saxon, Division of Clinical Immunology/ Allergy, UCLA School of Medicine, Los Angeles, CA)-coated-96 well flat ELISA plates with control human IgG, IgM, and IgA purchased from Sigma Chemical and IgE from Chemicon International Inc. (Temecula, CA). After an overnight incubation, supernatants were discarded and the wells were washed with 0.05% Tween 20 in PBS. Bound human Ig was detected with alkaline phosphatase-labeled goat anti-human IgG, IgM, IgA, or IgE (Sigma) at a dilution of 1/2,500, and color detection was performed. In this ELISA system, no cross-reaction among IgG, IgM, IgA, and IgE occurred.
Analysis of Somatic Hypermutation
Total RNA was isolated from PB MNCs using the GlassMax RNA isolation kit (GIBCO BRL, Gaithersburg, MO) and then reverse-transcribed into cDNA using oligo(dT) primer and Superscript II reverse transcriptase (GIBCO BRL). VH5 genes were amplified using primers corresponding to the 5Ј region of VH5 leader sequence (ATGGGGTCAACCGCCATCCT) and to the 3Ј C constant region (GTCCTGTGCGAG-GCAGCCAA). PCR products were ligated into the pCR2.1 vector (Invitrogen, Carlsbad, CA) and transformed into TOP10FЈ bacteria (Invitrogen). Individual clones were selected and expressed, and plasmid DNA was purified. DNA sequencing was performed by the Dideoxy Termination technique using an ABI 377 sequencer. 
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RESULTS
T-Cell Function in CVID Patients
We assessed T-cell proliferation and CD154 expression to estimate T-cell function in response to in vitro activation. T cells of CVID patients (n ϭ 16) proliferated when stimulated with PHA similar to normal controls (n ϭ 16) (data not shown). To determine optimal CD154 expression, we analyzed CD4 ϩ T cells following activation with PMA and ionomycin. Decreased CD154 expression by activated CD4 ϩ cells was observed in one-third of the patients studied, all having normal CD154 sequences, while the remaining two-thirds of CVID patients displayed normal levels of CD154 expression (data not shown). These findings demonstrate that the majority of CVID patients studied have normal T-cell functions but that a subset has a T-cell activation defect characterized by reduced CD154 expression, as previously reported (27) .
Memory B Cells in Patients with CVID
Although the number of circulating peripheral blood B cells was known to be within the normal range, serum immunoglobulin levels were reduced and in vivo immunoglobulin synthesis was defective in most CVID patients (Table 1 ). These observations prompted us to investigate B-cell characteristics by analyzing the phenotype of circulating B cells. As previously reported (12), adult peripheral blood B cells can be subdivided into two distinct subtypes: CD27 ϩ memory B cells and CD27
Ϫ naive B cells. CD27 ϩ B cells can be further subdivided by their capability to express IgD. In contrast, cord blood B cells and peripheral blood B cells of XHIM patients consist predominantly of CD27 Ϫ naive B cells (9, 16) .
Flow cytometric analysis of PB MNCs revealed that the number of IgD Ϫ CD27 ϩ memory B cells was greatly reduced in all patients studied when compared with normal controls (Fig.1) , while the percentages of IgD ϩ
CD27
ϩ B cells were diminished in 8 patients, increased in 3 patients, and normal in 13 patients. To confirm that the majority of circulating B cells in CVID are functionally naive, we examined the extent of somatic hypermutation of Ig-V-region genes. VH5 sequences showed no or very few changes of nucleotides or amino acids in patients lacking (Fig. 2) . In contrast, VH5 sequences obtained from 5 adult controls were highly mutated with an average mutation frequency of 1.8 Ϯ 0.5% ranging from 1.1 to 2.3%. These results indicate that the majority of B cells in CVID patients are phenotypically and functionally naive and that the IgD ϩ CD27 ϩ B cells observed in CVID patients were not functional memory B cells. 
MEMORY B CELLS AND COMMON VARIABLE IMMUNODEFICIENCY
In Vitro Production of Ig by PBMNCs from CVID Patients
The in vitro production of IgG, IgM, IgA, and IgE by activated circulating B cells is shown in Fig. 3 . When stimulated with SAC plus IL-2, which induces memory B cells to initiate Ig production, PB MNCs from CVID patients failed to secrete, or secreted only very low levels of IgA and low to moderate levels of IgM and IgG. However, when stimulated with a combination of SAC, CD40/CD32T, IL-2, and IL-10, a group of stimulants that induces Ig production not only by memory B cells but also by naive B cells, PB MNCs from most CVID patients produced IgG and IgM levels comparable to those of normal subjects. No significant difference in IgE production was observed in response to stimulation with IL-4 and CD40/CD32T between CVID patients and healthy subjects, except for 5 CVID patients who failed to generate IgE. Thus, CVID B cells are functionally 
DISCUSSION
Attempts have been made to classify CVID on the basis of in vitro immunoglobulin synthesis (1, 28 -30) and abnormal T-cell function (27, 31, 32) . However, these studies generally lacked vigorous assessment of differences in clinical presentation, course, and outcome of the disease. Thus, although the immunological abnormalities associated with CVID have been described in detail, no unifying hypotheses as to the molecular basis of CVID have been proposed (1) . To better understand the humoral defect of CVID, we studied 24 patients with CVID for the presence of memory B cells, the extent of somatic hypermutation, and in vitro B-cell function.
The diagnosis of CVID is generally one of exclusion and based on the absence of a family history compatible with X-linked inheritance, late onset of symptoms, the presence of B cells, and reduced but not absent serum immunoglobulins. Webster and co-workers divided CVID patients into three groups: Group A patients have a reduced number of circulating B cells that make neither IgG nor IgM; Group B patients have B cells that make IgM but not IgG; and Group C patients have normal numbers of B cells which can produce IgG and IgM in normal amounts (1). The majority of CVID
FIG. 3.
Immunoglobulin production by B cells from CVID patients. The quantity of Ig produced by PB MNCs from control individuals on the open symbols (n ϭ 12) or CVID patients (n ϭ 22) on the solid symbols is shown. PB MNCs were stimulated for 8 days and supernatants were analyzed for IgA, IgM, and IgG. To measure IgE production, PB MNCs were cultured for 12-14 days. Ig concentrations in the resultant supernatants were measured by ELISA. Final concentrations of SAC, IL-2, anti-CD40, IL-4, and IL-10 were 0.01%, 50 U/ml, 1 g/ml, 50 ng/ml, and 50 ng/ml, respectively. 39 patients presented here had typical clinical and laboratory findings, most closely resembling patients in Group C. The diagnoses of XLA and XHIM were excluded by a negative family history and by demonstrating cytoplasmic Btk and normal surface expression of CD40L in all male patients. Although we have not sequenced the gene responsible for XLP (SH2DA1/ SAP), we are confident that none of the male patients had XLP: none of the patients reported a severe case of mononucleosis and none has developed a lymphoma. Because serum IgM levels were low or normal, in vitro IgE synthesis was normal in most patients and, none of the patients had hypertrophic tonsils and lymphoadenopathy, we also excluded hyper-IgM syndrome due to mutations of AID (18) .
Although most CVID patients have normal numbers of circulating B cells, CVID B cells failed to differentiate into immunoglobulin-secreting plasma cells in vivo (15) . This differentiation defect has been correlated with low serum immunoglobulin levels and abnormal antibody responses to immunization with protein and polysaccharide antigens (15 (Fig. 3 ). Since patients with AID mutations consistently failed to produce IgE (18, and our unpublished data), the diagnosis of AID deficiency in these five patients must be considered; however, none of our patients had elevated IgM and large tonsils. In hyper-IgM patients due to mutations of AID, circulating B cells express CD27 (18) , a majority of which are IgD ϩ CD27 ϩ (our unpublished data), but have not undergone somatic hypermutation, implying that patients with AID mutations have CD27 ϩ B cells that are functionally naive, similarly to CVID patients.
A number of molecules involved in B-cell activation, proliferation, and differentiation are potential candidates for causing CVID (19 -22) . Susceptibility genes for CVID within the MHC class II and III loci have been reported (35, 36) . Because CD27 was expressed on T cells of all our patients (data not shown), defective CD27 is not the cause of CVID. Since PI3K Ϫ/Ϫ mice are known to cause B-cell abnormalities (19) , we explored the possibility that mutation of the PI3K gene may be involved in CVID patients. However, normal bands of the p85␣ subunit of PI3K were observed by Western blot analysis in all 17 patients studied (Suzuki, Koyashu, Agematsu, and Komiyama, unpublished data). Similarly, SWAP-70, a B-cell-specific component of an isotype switch recombination complex (SWAP) was found to be normal in 30 CVID patients reported by Rapalus et al. (37) .
In conclusion, although the clinical and immunological features of CVID are heterogeneous and the fundamental causes of CVID remain unknown, we report here that circulating CVID B cells, independent of their IgD ϩ CD27 ϩ status, have the characteristic of naive B cells and these resembling B cells present in cord blood and in the circulation of X-linked HIM patients, implying a defect in B-cell development. The failure of germinal center formation in CVID suggests that B-cell differentiation is not caused by a defect 40 intrinsic to B cells. Rather, B cells of a majority of CVID patients either cannot respond to signals from T cells or do not receive signals due to an intrinsic T-cell defect. As a result they fail to progress to IgD Ϫ CD27 ϩ memory B cells. Based on these facts, we hypothesize that one or more crucial signaling molecules required to induce terminal differentiation into memory B cells, if defective, may cause CVID.
